Telix Pharmaceuticals Limited · ASX:TLX
Telix Pharmaceuticals — Merger or Acquisition (January 2025)
14 slides from Telix Pharmaceuticals's merger presentation, Jan 13, 2025
Slide 1: Acquisition of Next-generation Therapeutic Assets and Novel Biologics Technology Platform
©) Telix Acquisition of Next-generation Therapeutic Assets and Novel Biologics Technology Platform Telix Pharmaceuticals NASDAQ: TLX | ASX: TLX January 2025
Slide 2: Disclaimer
Disclaimer This presentation should be read together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our registration statement on Form 20-F filed with the SEC, or on our we
Slide 3: Transaction to acquire novel biologics platform and assets
Transaction to acquire novel biologics platform and assets Platform, pipeline, and people from ImaginAb Inc. Transaction provides 1. Platform: a proprietary technology platform to generate unique theranostic Telix with multiple (therapeutic + diagnostic) engineered antibodies as radiopharmaceutical
Slide 4: Deal summary
Deal summary Structure: Asset Purchase Agreement with concurrent Technology License Agreement providing additional exclusive and non-exclusive rights to specific patents and know-how retained by ImaginAb. Assets Platform Technology; ongoing Designated Programs; Discovery-Stage Assets; Materials, Equ
Slide 5: Engineered antibody targeting agents offer best of both worlds
Engineered antibody targeting agents offer best of both worlds Bridging the gap between small molecules and antibodies ‘Antibody fragments’ ' Small | Nanobody scFv Diabody Minibody scFv-Fe IgGACH2 ' IgG ' 1 have a molecular ' molecue! 1 1 weight between full | P°PNC? 1 gg Aa : Y a ® a 1 j length ant
Slide 6: A platform technology ideal for radiopharmaceuticals
A platform technology ideal for radiopharmaceuticals Proprietary technology to develop protein-based therapeutic agents Advantage vs. antibodies Advantage vs. small molecules Favorable in vivo targeting characteristics’ + Faster tumor uptake * High affinity and targeting selectivity * High tumor pen
Slide 7: New pipeline of therapeutic assets
New pipeline of therapeutic assets Lead compounds validate the utility of the technology platform * The acquisition adds a pipeline of therapeutic compounds addressing commercially valuable indications with high unmet clinical need Lead IND? enabling selection stu Program Target/Indication Discovery
Slide 8: Integrin avB6 (IAB56) and new high-value targets
Integrin avp6 (IAB56) Highly expressed across range of cancers with high unmet need including — 90%+ of ovarian cancer’, 19k U.S. patients diagnosed p.a.* — 90%+ of pancreatic cancer’, 66k U.S. patients diagnosed p.a.* — 50%+ of non-small cell lung cancer (NSCLC), 187k+ U.S. patients diagnosed p.a.*
Slide 9: Integrin avB6 targeting: Preclinical summary (IAB56)
Integrin av6 targeting: Preclinical summary (IAB56)' Favorable dosimetry and efficacy * Tumor targeting demonstrated in multiple relevant tumor xenograft models Preclinical efficacy in multiple pancreatic cancer models * Efficacy studies highly reproducible, demonstrating significant tumor growth in
Slide 10: DLL3 targeting: Preclinical summary (IAB57)
DLL3 targeting: Preclinical summary (IAB57)' Demonstrated efficacy in an unmet clinical need + Tumor targeting demonstrated in multiple SCLC Preclinical efficacy in lung cancer model xenograft models Vehicle + 1AB57 shows excellent manufacturability properties 2500 cece and cross-reactivity to ortho
Slide 11: Clinical proof of concept
Clinical proof of concept Demonstrates highly specific targeting of cancer with favorable pharmacokinetics‘ 99mT¢-MDP 18F-FDG 897r-/AB2M va) Serum clearance 6 Tumor uptake + IAB2M Bone & od ¢ 30 cd & IAB2M Soft T 3 tee , a 2 + IgG Bone ' Pee 4 8 IgG Soft > . S 20 : j 2 1s 3 . 2g E B10 # > s 5 1AB2M.
Slide 12: Discovery platform, people and lab to bolster R&D capability
Discovery platform, people and lab to bolster R&D capability A faster way to develop candidates across a range of cancer indications Rapid “concept to clinical” model + Research and Development laboratory and team provides Telix with ability to identify, characterize and validate future therapeutic
Slide 13: Transaction summary
Transaction summary Reinforcing leadership position in theranostics Platform Proprietary technology to generate engineered antibody targeting agents * Bespoke radiopharmaceuticals balancing tumor uptake and blood clearance « Rapid development of new assets with optimized therapeutic profile + In-hou
Slide 14: Contact details
Contact details: Kyahn Williamson SVP Investor Relations and Corporate Communication kyahn.williamson@telixoharma.com
Telix Pharmaceuticals — Merger or Acquisition (January 2025) on 6ix